Jaguar Gene Therapy Community Letter & FAQ *UPDATED 11/5/24*
Jaguar has released an updated community letter and FAQ document that provides new details about the JAG201 clinical study. This resource…
Jaguar has released an updated community letter and FAQ document that provides new details about the JAG201 clinical study. This resource…
Neuren has released a statement that the drug was found to be generally safe at the dose tested, having no serious adverse effects.
Neuren has released a statement that the drug was found to be generally safe at the dose tested, having no serious adverse effects.
This EL-PFDD meeting was modeled after the work of the FDA’s Patient Focused Drug Development (PFDD) initiative. PFDD is a systematic way of gathering patient perspectives on their condition and on available treatments. The information gathered at the meeting is presented in this Voice of the Patient report, a high-level summary of the perspectives generously shared by the families and caregivers of individuals living with PMS, who participated in the November 8, 2022, EL-PFDD meeting. The report also includes selected comments that were submitted through an online portal.